GlassScriptPhysician profile
Stephen P Hall
NPI 1740211184
$928.13
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $674 · 2020: $53.24 · 2023: $77.92 · 2024: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $200.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Comsort, INC | $250.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.04 | 2019-2020 | |
| Pfizer INC. | $108.14 | 2019-2024 | |
| Astellas Pharma US INC | $54.04 | 2019-2020 | |
| Amgen INC. | $49.26 | 2019 | |
| Lilly USA, LLC | $43.43 | 2019-2023 | Mounjaro |
| Novo Nordisk INC | $40.06 | 2019-2024 | Rybelsus, Ozempic |
| Abbvie INC. | $32.67 | 2024 | |
| Sanofi Pasteur INC. | $26.86 | 2023 | |
| Roche Diagnostics Corporation | $25.05 | 2019 | |
| Allergan, INC. | $23.61 | 2019 | |
| Merck Sharp & Dohme LLC | $22.49 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $22.47 | 2023 | Eliquis |
| Pacira Therapeutics, INC. | $20.66 | 2019 | |
| Acorda Therapeutics, INC | $18.37 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $17.53 | 2024 | |
| Genentech USA, INC. | $15.04 | 2020 | |
| Glaxosmithkline, LLC. | $14.45 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.